Indigestion sufferers across England could soon receive quick capsule sponge tests to screen for oesophageal cancer under draft recommendations from the National Institute for Health and Care Excellence, BBC News reported.
Between one and two adults in every 100 have Barrett’s oesophagus, a condition where cells in the food pipe start to change due to acid exposure, according to BBC News. Most patients never develop cancer, but high demand for hospital endoscopies means some individuals with the condition are not monitored as frequently as medical guidelines recommend.
The proposed expansion aims to relieve pressure on National Health Service resources by replacing complex camera procedures with a rapid procedure performed in primary care settings. Final recommendations from NICE are expected in the new year.
When a doctor gently pulls the thread back out through the mouth, the sponge collects cells from the lining of the gullet for laboratory analysis.
Cytosponge Test Reduces Discomfort but Requires Ongoing Monitoring
- Less Invasive Screening: The cytosponge test replaces traditional hospital cameras with a swallowed capsule on a string, reducing physical discomfort for patients with chronic acid reflux.
- Long-Term Monitoring Still Required: An all-clear result on a sponge test does not eliminate the need for ongoing medical supervision, as no single diagnostic tool captures every case.
Draft Guidance Expands Access
Draft guidelines from NICE state that sponge tests, which are already operational in pilot programmes across parts of the country, should be offered more widely to patients with bad indigestion and reflux disease, BBC News reported. The approach is designed to catch Barrett’s oesophagus and early oesophageal cancer before symptoms worsen.

Nottingham Post reported that the test takes only minutes to perform.
Prof Jonathan Benger, chief executive of NICE, said sponge tests offer a “quick and less invasive” way to detect concerning changes, helping to identify people who should go on to have further tests and treatment, according to the BBC.
“The NHS is always looking for better ways to get to the bottom of people’s symptoms, and thousands have already benefited from this incredibly efficient test through pilots we have been running, so it’s fantastic it is now being considered for roll out across the country,” said Prof Peter Johnson, national clinical director for cancer at NHS England.
“Many people have acid reflux, and having an easier way to check for changes in the lining of the oesophagus can make a big difference for patients, reducing the need for more complicated endoscopy tests and helping the NHS free up resources to find cancers at an earlier stage,” Prof Peter Johnson, national clinical director for cancer at NHS England, said.
Risk Factors Trigger Barrett’s Oesophagus and Necessitate Monitoring
Risk factors such as smoking, alcohol consumption, and carrying excess body weight can worsen the condition over time.
When stomach acid damages the lining of the gullet repeatedly, it can trigger cellular mutations leading to Barrett’s oesophagus.
NICE emphasised that no diagnostic test, including standard endoscopy, identifies every case. Individuals who receive a negative result on a sponge test must still remain under long-term clinical monitoring.
Future Implementation in the New Year
The draft recommendations remain open through the consultation phase, with NICE scheduled to release its final guidance in the new year. If fully adopted, the rollout will make the screening tool available to thousands more patients experiencing persistent indigestion across England.
Final recommendations from NICE will be made in the new year, according to BBC News.
References
- National Institute for Health and Care Excellence (NICE). Draft guidance on cytosponge tests for Barrett’s oesophagus and oesophageal cancer.
- NHS England. Clinical director statements and pilot program outcome summaries.
- BBC News. Cancer ‘sponge’ tests could be offered to more people with bad indigestion.